Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAV-240 for moderate-to-severe hidradenitis suppurativa
2025-523557-33-00Phase 2Authorised
- Sponsor
- Navigator Medicines
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing NAV-240 with Placebo (2 arms). Primary endpoint: HiSCR75 response at Week 16. Planned start Apr 2026; status: authorised.
02
Drugs
NAV-240
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2025-523557-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523557-33-00.